J Gynecol Oncol.  2015 Apr;26(2):156-167. 10.3802/jgo.2015.26.2.156.

Major clinical research advances in gynecologic cancer in 2014

• Suh DH
• Lee KH
• Kim K
• Kang S
• Kim JW

• KMID: 2160800
• DOI: http://doi.org/10.3802/jgo.2015.26.2.156

Abstract

In 2014, 9 topics were selected as major advances in clinical research for gynecologic oncology: 2 each in cervical and corpus cancer, 4 in ovarian cancer, and 1 in breast cancer. For cervical cancer, several therapeutic agents showed viable antitumor clinical response in recurrent and metastatic disease: bevacizumab, cediranib, and immunotherapies including human papillomavirus (HPV)-tumor infiltrating lymphocytes and Z-100. The HPV test received FDA approval as the primary screening tool of cervical cancer in women aged 25 and older, based on the results of the ATHENA trial, which suggested that the HPV test was a more sensitive and efficient strategy for cervical cancer screening than methods based solely on cytology. For corpus cancers, results of a phase III Gynecologic Oncology Group (GOG) 249 study of early-stage endometrial cancer with high-intermediate risk factors are followed by the controversial topic of uterine power morcellation in minimally invasive gynecologic surgery. Promising results of phase II studies regarding the effectiveness of olaparib in various ovarian cancer settings are summarized. After a brief review of results from a phase III study on pazopanib maintenance therapy in advanced ovarian cancer, 2 outstanding 2014 ASCO presentations cover the topic of using molecular subtypes in predicting response to bevacizumab. A review of the use of opportunistic bilateral salpingectomy as an ovarian cancer preventive strategy in the general population is presented. Two remarkable studies that discussed the effectiveness of adjuvant ovarian suppression in premenopausal early breast cancer have been selected as the last topics covered in this review.

Keyword

Angiogenesis Inhibitor; Breast Neoplasm; Early Detection of Cancer; Leiomyosarcoma; Ovarian Neoplasm; Poly (ADP-ribose) Polymerase

MeSH Terms

Biomedical Research/*trends
Endometrial Neoplasms/drug therapy/pathology/surgery
Female
Genital Neoplasms, Female/diagnosis/*therapy
Humans
Ovarian Neoplasms/drug therapy/pathology/surgery
Uterine Cervical Neoplasms/drug therapy/pathology/surgery

Reference

1. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: a NRG Oncology-Gynecologic Oncology Group study. Ann Oncol. 2014; 25:Suppl 4. LBA26.

2. Symonds P, Gourley C, Davidson S, West C, Dive C, Paul J, et al. CIRCCA: a randomised double blindphase II trial of carboplatin-paclitaxel plus cediranib versuscarboplatin-paclitaxel plus placebo inmetastatic/recurrent cervical cancer (CRUK GRANT REF: C1256/A11416). Ann Oncol. 2014; 25:Suppl 4. LBA25–LBAPR.

3. Hinrichs CS, Stevanovic S, Draper L, Somerville R, Wunderlich J, Restifo NP, et al. HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. J Clin Oncol. 2014; 32:18 Suppl. LBA3008.

4. Sugiyama T, Fujiwara K, Ohashi Y, Yokota H, Hatae M, Ohno T, et al. Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study. Ann Oncol. 2014; 25:1011–1017.

5. Noda K, Ohashi Y, Okada H, Ogita S, Ozaki M, Kikuchi Y, et al. Randomized phase II study of immunomodulator Z-100 in patients with stage IIIB cervical cancer with radiation therapy. Jpn J Clin Oncol. 2006; 36:570–577.

6. Noda K, Ohashi Y, Sugimori H, Ozaki M, Niibe H, Ogita S, et al. Phase III double-blind randomized trial of radiation therapy for stage IIIb cervical cancer in combination with low- or high-dose Z-100: treatment with immunomodulator, more is not better. Gynecol Oncol. 2006; 101:455–463.

7. Society of Gynecologic Oncology. Women's Cancer News. FDA panel approves primary HPV screening tool [Internet]. Irving, TX: Multibriefs;2014. cited 2015 Jan 28. Available from: http://multibriefs.com/briefs/SGO/SGO122914.php.

8. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013; 121:829–846.

9. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011; 12:880–890.

10. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011; 135:468–475.

11. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014; 383:524–532.

12. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007; 357:1589–1597.

13. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007; 370:1764–1772.

14. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012; 13:78–88.

15. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009; 10:672–682.

16. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010; 11:249–257.

17. Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014; 15:172–183.

18. Landrum LM, Nugent EK, Zuna RE, Syzek E, Mannel RS, Moore KN, et al. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol. 2014; 132:50–54.

19. McMeekin DS, Filiaci VL, Aghajanian C, Cho J, Kim JW, DiSilvestro PA, et al. Randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/ carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a Gynecologic Oncology Group trial. Gynecol Oncol. 2014; 134:438.

20. Edelson MI, Chen LM, Burke WM. Society of Gynecologic Oncology Clinical Practice Committee. Postoperative radiation therapy for endometrial cancer: where do we go from here? Pract Radiat Oncol. 2014; 4:145–146.

21. Park JY, Park SK, Kim DY, Kim JH, Kim YM, Kim YT, et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol. 2011; 122:255–259.

22. Kho KA, Nezhat CH. Evaluating the risks of electric uterine morcellation. JAMA. 2014; 311:905–906.

23. Seidman MA, Oduyebo T, Muto MG, Crum CP, Nucci MR, Quade BJ. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS One. 2012; 7:e50058.

24. Society of Gynecologic Oncology. SGO position statement: morcellation [Internet]. Chicago, IL: Society of Gynecologic Oncology;2014. cited 2015 Mar 9. Available from: https://www.sgo.org/newsroom/position-statements-2/morcellation/.

25. Society of Gynecologic Oncology. Statement of the Society of Gynecologic Oncology to the Food and Drug Administration's Obstetrics and Gynecology Medical Devices Advisory Committee concerning safety of laparoscopic power morcellation [Internet]. Chicago, IL: Society of Gynecologic Oncology;2014. cited 2015 Mar 9. Available from: https://www.sgo.org/wp-content/uploads/2014/04/SGO-Testimony-to-FDA-on-Power-Morcellation-FINAL.pdf.

26. Hagemann IS, Hagemann AR, LiVolsi VA, Montone KT, Chu CS. Risk of occult malignancy in morcellated hysterectomy: a case series. Int J Gynecol Pathol. 2011; 30:476–483.

27. Leibsohn S, d'Ablaing G, Mishell DR Jr, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990; 162:968–974.

28. Patient safety must be a priority in all aspects of care. Lancet Oncol. 2014; 15:123.

29. Goff BA. SGO not soft on morcellation: risks and benefits must be weighed. Lancet Oncol. 2014; 15:e148.

30. US Food and Drug Administration. FDA news release: FDA discourages use of laparoscopic power morcellation for removal of uterus or uterine fibroids [Internet]. Silver Spring, MD: US Food and Drug Administration;2014. cited 2015 Mar 9. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393689.htm.

31. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361:123–134.

32. Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol. 2014; 133:362–369.

33. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014; 15:852–861.

34. Curigliano G. From precision medicine to cancer care through the immunome: highlights from the European Society of Medical Oncology Congress, Madrid, 26-30th September 2014. Ecancermedicalscience. 2014; 8:472.

35. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015; 16:87–97.

36. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014; 15:1207–1214.

37. Suh DH, Kim JW, Kang S, Kim HJ, Lee KH. Major clinical research advances in gynecologic cancer in 2013. J Gynecol Oncol. 2014; 25:236–248.

38. Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, et al. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013; 49:2972–2978.

39. Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, et al. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin Cancer Res. 2015; Jan. 14. [Epub]. http://dx.doi.org/10.1158/1078-0432.CCR-14-2565.

40. Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol. 2012; 124:347–353.

41. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014; 20:764–775.

42. du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014; 32:3374–3382.

43. Liu J, Matulonis UA. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin Cancer Res. 2014; 20:5150–5156.

44. Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, et al. Better therapeutic trials in ovarian cancer. J Natl Cancer Inst. 2014; 106:dju029.

45. Gourley C, McCavigan A, Perren T, Paul J, Michie CO, Churchman M, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol. 2014; 32:15 Suppl. 5502.

46. Winterhoff BJ, Kommoss S, Oberg AL, Wang C, Riska SM, Konecny GE, et al. Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. J Clin Oncol. 2014; 32:15 Suppl. 5509.

47. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609–615.

48. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer: shifting the paradigm. Hum Pathol. 2011; 42:918–931.

49. Schenberg T, Mitchell G. Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: a mini-review. Front Oncol. 2014; 4:21.

50. Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol. 2013; 129:448–451.

51. Findley AD, Siedhoff MT, Hobbs KA, Steege JF, Carey ET, McCall CA, et al. Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial. Fertil Steril. 2013; 100:1704–1708.

52. Falconer H, Yin L, Gronberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst. 2015; 107:dju410.

53. Narod SA. Salpingectomy to prevent ovarian cancer: a counter-currents series. Curr Oncol. 2013; 20:145–147.

54. Kwon JS, McAlpine JN, Hanley GE, Finlayson SJ, Cohen T, Miller DM, et al. Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol. 2015; 125:338–345.

55. Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, et al. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 2013; 22:1094–1100.

56. Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015; 372:436–446.

57. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014; 371:107–118.